EOM 1352: Fri 7 June 2024, 11:36
Catalyst 7 July 2023, 14:52

Current Edition

Discovery Park: Wed 13 November 2024, 10:35
ramusmedical

Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Part 2: Considerations for Planning and Conducting Clinical Trials

Nonalcoholic fatty liver disease (NAFLD) is a widespread cause of
chronic liver disease (CLD) and liver-related morbidity and mortality,
and is the most common cause of CLD in North America. This paper,
the second in a two-part series by Dr Mark DeLegge of NASH
Focus Group addressing nonalcoholic steatohepatitis, provides an
overview of these important diseases.

Catalyst: Fri 8 November 2024, 14:16
Biosynth: Wed 13 November 2024, 10:18